secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001628280-24-042833
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Paige Mahaney as CSO; Stewart Fisher retires effective Oct 28
--------------------------------------------------------------------------------

- Paige Mahaney, Ph.D., appointed Chief Scientific Officer effective October 28, 2024; succeeds Stewart Fisher.
- Fisher will remain as Senior Scientific Advisor through Dec 31, 2024, then consultant through Dec 31, 2025.
- Mahaney joins from Exelixis; receives $510K base salary, $150K sign-on bonus, and 345,600 stock options.
- Fisher's retirement not due to any disagreement; entered consulting agreement for continued vesting of equity.
- Mahaney brings over 25 years pharma experience, most recently SVP of drug discovery at Exelixis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042833/0001628280-24-042833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042833/cccc-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer